Urogen Pharma $URGN Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System lifted its position in Urogen Pharma (NASDAQ:URGN) by 1,605.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 38,750 shares of the company’s stock after buying an additional 36,478 shares during the quarter. California State Teachers Retirement System’s holdings in Urogen Pharma were worth $697,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares during the period. Russell Investments Group Ltd. increased its stake in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares during the period. Osaic Holdings Inc. lifted its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the period. Finally, ProShare Advisors LLC purchased a new position in shares of Urogen Pharma in the fourth quarter valued at approximately $206,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Trading Up 0.2%

Shares of NASDAQ:URGN opened at $48.22 on Friday. The business has a 50-day moving average price of $38.53 and a two-hundred day moving average price of $28.11. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $49.67. The stock has a market capitalization of $2.36 billion, a P/E ratio of -24.35 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. As a group, equities analysts predict that Urogen Pharma will post -0.2 EPS for the current year.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the insider directly owned 119,763 shares of the company’s stock, valued at approximately $4,790,520. This represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 25,222 shares of company stock valued at $892,661. Corporate insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on URGN. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. HC Wainwright boosted their price target on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Oppenheimer upped their price objective on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research report on Thursday, July 16th. Finally, Guggenheim raised their target price on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.78.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.